- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX Reports Strong Revenue Growth for Three Months and Six Months Ended April 30, 2026 | 276 | ACCESS Newswire | Company reports revenue growth of 124.6% for the quarter ended April 30, 2026 and 79.9% for the six months ended April 30, 2026, as compared to the same periods one year earlier as commercial momentum... ► Artikel lesen | |
| 01.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX to Host Live Educational Webinar for Healthcare Professionals Exploring the Southeast Regenerative Medicine Revolution | 321 | ACCESS Newswire | "One Year Later, Three States Stronger" program will examine lessons learned from Florida's first year into their pioneering stem cell law and provide physicians from other states an insight of what... ► Artikel lesen | |
| 16.06. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| ZEO SCIENTIFIX Aktie jetzt für 0€ handeln | |||||
| 16.06. | Zeo ScientifiX, Inc.: ZEO ScientifiX Donates Products to Support Pediatric Burn Reconstruction Mission in Peru | 201 | ACCESS Newswire | ZEO Medical Advisory Board Member Dr. Constantino Mendieta joins humanitarian effort providing reconstructive care to children recovering from severe burn injuries in Cusco, Peru DAVIE, FL / ACCESS... ► Artikel lesen | |
| 15.06. | Zeo ScientifiX, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.06. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.06. | Zeo ScientifiX, Inc.: ZEO ScientifiX Expands Medical Advisory Board with Leaders in Regenerative and Longevity Medicine | 470 | ACCESS Newswire | Company strengthens scientific leadership as regenerative medicine gains national momentum DAVIE, FL / ACCESS Newswire / June 9, 2026 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) ("ZEO ScientifiX" or the "Company")... ► Artikel lesen | |
| 27.05. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | Zeo ScientifiX, Inc.: ZEO ScientifiX Launches Physician-Led Patient Masterclass Program Following Grassroots Demand in the Southeast | 578 | ACCESS Newswire | After training more than 600 physicians in under a year, the biologics research and products company now turns its focus to assisting physicians in educating their patients on the science of regenerative... ► Artikel lesen | |
| 12.05. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.05. | Zeo ScientifiX, Inc.: ZEO ScientifiX Announces That Unaudited Monthly Sales Surpassed $1.0 million in April 2026, the First Time The Company Has Achieved This Milestone. | 203 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / May 12, 2026 / ZEO ScientifiX (OTCQB:ZEOX) ("ZEO" or the "Company"), a regenerative medicine products company serving physician-run clinics across the United... ► Artikel lesen | |
| 21.04. | Zeo ScientifiX, Inc.: ZEO ScientifiX Surpasses 500 Physicians Trained in Regenerative Medicine Compliance; Monthly Masterclasses Average 70+ Clinicians | 198 | ACCESS Newswire | DAVIE, FL / ACCESS Newswire / April 21, 2026 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) ("ZEO ScientifiX"), a provider of industry-leading clinical education in regenerative medicine innovation, proudly announces... ► Artikel lesen | |
| 21.04. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.04. | Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics--Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX | 2 | CNW | ||
| 09.04. | Zeo ScientifiX, Inc.: Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics - Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX | 448 | ACCESS Newswire | Regen Therapy's 24,000-practitioner network will unlock a fully integrated care ecosystem - featuring Stealth Health's licensed prescriber team and specialized therapies, Metabolic Code-driven longevity... ► Artikel lesen | |
| 07.04. | Zeo ScientifiX, Inc.: ZEO ScientifiX Selected as Qualified Team Advancing into the XPRIZE Healthspan Semi-Finals Stage | 454 | ACCESS Newswire | DAVIE, FL / ACCESS Newswire / April 7, 2026 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) ("ZEO" or the "Company"), a clinical-stage biotechnology company, today announced its selection as a Qualified Team advancing... ► Artikel lesen | |
| 07.04. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,965 | -0,55 % | Qiagen: Die Gerüchte gehen in die zweite Runde | Im Januar wurde gemunkelt, Qiagen könnte unmittelbar vor einer Übernahme stehen. Doch am Ende verlief die Sache im Sand. Die Aktie, die damals einen Riesensatz nach oben gemacht hatte, fiel tiefer als... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,99 | -0,01 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ERASCA | 19,160 | -0,05 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| TREVI THERAPEUTICS | 19,075 | +0,03 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,500 | -1,58 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,060 | +2,95 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,42 | +2,02 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| KYMERA THERAPEUTICS | 115,77 | +1,56 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,530 | -3,03 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 28,490 | +3,08 % | Mizuho hebt Kursziel für Tango Therapeutics nach vielversprechenden Studiendaten an | ||
| NURIX THERAPEUTICS | 23,120 | 0,00 % | Mizuho hebt Kursziel für Nurix nach Roche-Deal auf 34 US-Dollar an | ||
| ARRIVENT BIOPHARMA | 33,190 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,960 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| CG ONCOLOGY | 71,92 | +3,48 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 42,620 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RAP-... ► Artikel lesen |
ZEO SCIENTIFIX INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZEO SCIENTIFIX INC finden Sie auf Wallstreet Online.